

# Hanna Mysliwiec

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113672/publications.pdf>

Version: 2024-02-01

35  
papers

526  
citations

687335

13  
h-index

713444

21  
g-index

35  
all docs

35  
docs citations

35  
times ranked

820  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid profile disturbances may predispose psoriatic patients to liver dysfunction. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 310-318.	0.9	5
2	Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Aging—A Systematic Review. <i>Cells</i> , 2021, 10, 813.	4.1	25
3	Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis. <i>Molecular Biology Reports</i> , 2021, 48, 4421-4429.	2.3	6
4	Antioxidant Barrier and Oxidative Damage to Proteins, Lipids, and DNA/RNA in Adrenal Tumor Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-19.	4.0	14
5	Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6317-6330.	3.5	5
6	Bariatric Surgery Normalizes Protein Glycoxidation and Nitrosative Stress in Morbidly Obese Patients. <i>Antioxidants</i> , 2020, 9, 1087.	5.1	20
7	The Impact of Hypertension and Metabolic Syndrome on Nitrosative Stress and Glutathione Metabolism in Patients with Morbid Obesity. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-10.	4.0	22
8	Impact of Weight Loss on the Total Antioxidant/Oxidant Potential in Patients with Morbid Obesity—A Longitudinal Study. <i>Antioxidants</i> , 2020, 9, 376.	5.1	19
9	A Longitudinal Study of the Antioxidant Barrier and Oxidative Stress in Morbidly Obese Patients after Bariatric Surgery. Does the Metabolic Syndrome Affect the Redox Homeostasis of Obese People?. <i>Journal of Clinical Medicine</i> , 2020, 9, 976.	2.4	27
10	Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin. <i>Lipids</i> , 2019, 54, 445-452.	1.7	6
11	Metabolic Syndrome is Associated with Ceramide Accumulation in Visceral Adipose Tissue of Women with Morbid Obesity. <i>Obesity</i> , 2019, 27, 444-453.	3.0	35
12	Serum sphingolipid level in psoriatic patients with obesity. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 714-721.	0.9	9
13	Abnormal serum fatty acid profile in psoriatic arthritis. <i>Archives of Medical Science</i> , 2019, 15, 1407-1414.	0.9	14
14	Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR). <i>Journal of Dermatological Treatment</i> , 2018, 29, 135-139.	2.2	6
15	Serum YKL-40 as a potential biomarker of inflammation in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 19-23.	2.2	15
16	Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. <i>Journal of Dermatological Treatment</i> , 2017, 28, 136-140.	2.2	14
17	Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. <i>Archives of Dermatological Research</i> , 2017, 309, 79-86.	1.9	50
18	Serum fatty acid profile in psoriasis and its comorbidity. <i>Archives of Dermatological Research</i> , 2017, 309, 371-380.	1.9	45

#	ARTICLE	IF	CITATIONS
19	Serum Fatty Acid-binding Protein 4 is Increased in Patients with Psoriasis. <i>Lipids</i> , 2017, 52, 51-60.	1.7	21
20	Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 786-790.	1.3	7
21	Serum irisin levels in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 304-308.	2.2	18
22	Selected aspects of apoptosis in psoriasis. <i>Przegląd Dermatologiczny</i> , 2017, 1, 57-63.	0.1	2
23	The role of lipids in psoriasis. <i>Przegląd Dermatologiczny</i> , 2017, 104, 619-635.	0.1	10
24	Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK). <i>Advances in Medical Sciences</i> , 2016, 61, 207-211.	2.1	10
25	Clinical and epidemiological assessment of patients hospitalized for primary and recurrent erysipelas. <i>Przegląd Epidemiologiczny</i> , 2016, 70, 575-584.	0.2	5
26	Upregulation of the sFas/sFasL system in psoriatic patients. <i>Advances in Medical Sciences</i> , 2015, 60, 64-68.	2.1	4
27	Creatinine or cystatin C – which is a better index of renal function in morbid obesity?. <i>Advances in Medical Sciences</i> , 2013, 58, 376-381.	2.1	8
28	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. <i>Cytokine</i> , 2013, 61, 690.	3.2	3
29	Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients. <i>Folia Histochemica Et Cytobiologica</i> , 2012, 50, 75-79.	1.5	11
30	Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients. <i>Folia Histochemica Et Cytobiologica</i> , 2012, 50, 75-9.	1.5	6
31	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. <i>Cytokine</i> , 2010, 52, 225-229.	3.2	35
32	Three cases of classic Kaposi's sarcoma with different subtypes of Kaposi's sarcoma-associated herpesvirus. <i>International Journal of Dermatology</i> , 2006, 45, 843-846.	1.0	8
33	Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 418-421.	2.4	13
34	Soluble tumor necrosis factor- $\alpha$ receptor type 1 during selenium supplementation in psoriasis patients. <i>Nutrition</i> , 2003, 19, 847-850.	2.4	22
35	Linear IgA bullous dermatosis in a diabetic patient with chronic renal failure. <i>International Journal of Dermatology</i> , 2002, 41, 778-780.	1.0	6